• Vol. 38 No. 11, 1011–1016
  • 15 November 2009

Abnormal Progesterone and Corticotropin Releasing Hormone Levels are Associated with Preterm Labour

26



ABSTRACT

Introduction: This study examined whether maternal plasma progesterone and corticotropin releasing hormone (CRH) concentrations can predict the likelihood of preterm labour. Materials and Methods: Maternal plasma progesterone and CRH concentrations were examined in a total of 51 women. The subject cohort included 20 women who were followed from the beginning of the third trimester (28 to 34 weeks gestation), half of whom delivered early preterm and half of whom were not in labour and subsequently delivered at full term (n = 10 per group). In a follow-up experiment, 31 women who were admitted during labour for delivery were examined, 15 of whom delivered preterm and 16 of whom delivered at full term. Comparisons between women who delivered preterm and those who delivered at full term were made by t-tests. Results: Mean progesterone concentration was approximately 30% lower at 28 to 34 weeks gestation in women who delivered prematurely than in women who delivered at term (P <0.001). Meanwhile, mean CRH concentration was 6-fold higher at 28 to 34 weeks gestation in women who experienced spontaneous preterm labour than in those who went into labour at term (P <0.001). Preterm mothers had lower progesterone (P <0.05) and CRH (P <0.01) levels during active labour than full-term mothers. Progesterone levels normalised within 24 hours of delivery in preterm mothers, while CRH levels remained slightly elevated (P <0.01). Conclusions: Maternal progesterone and CRH measurements taken early in the third trimester may be of use as biochemical markers of pregnancies at high risk of premature labour.


Preterm labour is a serious obstetrical problem. Indeed, approximately 10% of all pregnancies are affected by preterm birth and 70% of neonatal morbidity and mortality can be attributed to preterm labour.1-3 Tocolytic and corticosteroid treatments have been used to attempt to inhibit preterm labour and ultimately to reduce the consequences of prematurity on neonates. However, these treatments have failed to reduce the rate of preterm birth.2,4,5 Progesterone is a vital gestational-support steroid hormone produced in the adrenal glands, corpus luteum, brain and placenta. Exogenous progesterone has been used to support assisted reproduction protocols, such as in vitro fertilisation,6 while progesterone receptor antagonists, such as mifepristone, have contraceptive and abortifacient effects.7,8 Moreover, progesterone supplementation has been reported to reduce the incidence of spontaneous preterm delivery in women at risk for premature labour.9

This article is available only as a PDF. Please click on “Download PDF” to view the full article.